Chronic Renal Insufficiency Clinical Trial
Official title:
Effects of Very Low Protein Diet Supplemented With Ketoanalogs on Renal Death in Phase 4/5 Chronic Kidney Disease (CKD) - ERIKA Study
The purpose of this study is to determine whether the use of a very low protein diet is effective in delaying the start of chronic dialysis treatment in patients affected by chronic kidney disease (CKD).
The prevalence of chronic dialysis patients is increasing worldwide because of the rising
incidence of end stage renal disease, it is burdened by high cardiovascular risk, it is
associated with a very high morbidity and mortality and it determines enormous costs for the
community.
The improvement in the management of metabolic and cardiovascular complication associated to
chronic kidney disease (CKD) since the early stages of the disease becomes mandatory in
order to delay the start of dialysis and to ameliorate the whole patient outcome.
Dietary protein restriction represents a basic therapeutic approach in CKD, by reducing the
accumulation of nitrogen catabolic substances, the phosphorus retention and the consequent
hyperparathyroidism, the metabolic acidosis, the salt intake and the consequent
hypertension, the proteinuria, and by improving the anemia and the glycemic tolerance, but
the effects of the low protein diet on renal failure progression rate have not been
definitely demonstrated.
Dietary effective reduction of just 0.2 g/kg/day of proteins is effective in ameliorating
blood urea nitrogen, metabolic acidosis and hyperphosphoremia, and the very low protein diet
(VLPD) allows a further improving of the metabolic control of uremia, it is safe, not
affecting the nutritional status, and it is cost saving. VLPD has been suggested to delay
the start of renal replacement therapy with respect to standard low protein diet, by mean of
either secondary analysis of clinical trials or retrospective analysis.
Large randomized clinical trials (RCT) on this issue lack, and the effect of VLPD on renal
death remain to be addressed. As well, information on patients' compliance to VLPD
prescription and on the impact of VLPD on the quality of life are needed. Finally, also the
effects of VLPD on both cardiovascular risk factors and mortality remain to be completely
evaluated.
The primary aim of this study is to evaluate, by mean of a RCT, the effect of the very low
protein diet on the renal death in renal patients affected by chronic renal insufficiency of
moderate to advanced degree (CKD stages 4 and 5). Secondary aims are to evaluate the effect
of VLPD on cardiovascular risk factors, morbidity and mortality, the adherence to VLPD, and
the relationship between VLPD and quality of life.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00968877 -
Vitamin D and Chronic Renal Insufficiency
|
Phase 3 | |
Terminated |
NCT00701714 -
Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients
|
Phase 3 | |
Completed |
NCT00998972 -
N-acetyl-cysteine (NAC) and Kidney Graft Function
|
Phase 3 | |
Completed |
NCT00716573 -
Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure
|
Phase 4 | |
Recruiting |
NCT04334707 -
Kidney Precision Medicine Project
|
||
Completed |
NCT02203084 -
Social Determinants in Chronic Disease in British Columbia
|
N/A | |
Recruiting |
NCT02147782 -
Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency
|
||
Completed |
NCT01029002 -
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT00742716 -
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT00095056 -
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
|
Phase 3 | |
Completed |
NCT00223548 -
MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application
|
Phase 2 | |
Completed |
NCT01574157 -
Investigations of the Optimum Serum Bicarbonate Level in Renal Disease.
|
N/A | |
Active, not recruiting |
NCT02751099 -
Bone and Cardiovascular Disease After Kidney Transplant
|
||
Recruiting |
NCT02002585 -
Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT01245374 -
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
|
Phase 4 | |
Completed |
NCT01252810 -
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
|
Phase 2 | |
Completed |
NCT00792857 -
Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)
|
Phase 1 | |
Completed |
NCT00888069 -
Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects
|
Phase 1 | |
Completed |
NCT00369733 -
STAAR-3 Clinical Study
|
Phase 4 | |
Recruiting |
NCT06362759 -
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
|
Phase 2 |